Figure 6.

β₁ integrin blockade alters diabetogenic T cell effector phenotype in the pancreas (PA). Irradiated InsHA-mCherry mice transferred with Clone 4-GFP CD8⁺ and HNT-CFP CD4⁺ T cells were treated with anti-β1 mAb or isotype control antibodies on days 8 and 9 after transfer. At day 10, donor T cells from pancreatic LN (pLN) and PA were analyzed by FACS gating on living CD8⁺ or CD4⁺ Thy1.1⁺ lymphocytes. (A) Donor T cells in the PA of treated mice. FACS event counts in the CD8⁺ or CD4⁺ Thy1.1⁺ gates from three independent experiments, represented as mean ± SEM (n = 8 mice, Mann–Whitney). (B) Donor T cell expression of CD25, CD62L, and KLRG1. Percentages of indicated subpopulations in the CD8⁺ Thy1.1⁺ or CD4⁺ Thy1.1⁺ gates from three independent experiments, represented as mean ± SEM (n = 8 mice, Mann–Whitney). (C) Intracellular cytokine measurement in donor T cells. Percentages of IL-2⁺ or IFNγ⁺ cells in the CD8⁺ Thy1.1⁺ or CD4⁺ Thy1.1⁺ gates from two independent experiments, represented as mean ± SEM (n = 6 mice, Mann–Whitney).